Please login to the form below
Faslodex
This page shows the latest Faslodex news and features for those working in and with pharma, biotech and healthcare.
Novartis claims a rare win at ESMO for PI3K inhibitor class
The results of the SOLAR-1 trial showed that giving alpelisib (BYL719) alongside AstraZeneca’s venerable product Faslodex (fulvestrant) improved progression-free survival (PFS) in patients with hormone ... months for patients receiving Faslodex alone
Latest news
-
CHMP recommends Teva's generic version of Astellas' Advagraf
The company also received a positive opinion on the extension of its breast cancer drug Faslodex (fulvertrant), which has been recommended to use as a monotherapy for oestrogen receptor positive, locally ... The committee also recommended that Faslodex
-
Dismay as NICE turns down first-line use of AZ's Faslodex
NICE also turned down Faslodex as a second-line therapy for hormone-receptor-positive patients in 2011. ... The NICE setback comes just a few days after AZ won FDA approval for Faslodex as a monotherapy in this patient group.
-
Pfizer’s first-in-class breast cancer therapy wins EU licence
months when combined with AstraZeneca's Faslodex (fulvestrant) compared to Faslodex alone. ... The studies also showed a significant improvement in patients' quality of life when taking Ibrance in comparison with Faslodex.
-
Lilly presses on with breast cancer study despite setback
Abemaciclib was being tested alongside AstraZeneca's hormonal therapy Faslodex (fulvestrant) as a first-line treatment for women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)
-
FDA deems ribociclib a breast cancer breakthrough
Novartis is carrying out trials of the drug in first-line settings in combination with AstraZeneca's hormonal therapy Faslodex (fulvestrant), as well as in pre-menopausal women and in adjuvant
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Can protein degraders unlock ‘undruggable’ drug targets?
this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by causing the oestrogen receptor to become more hydrophobic and stimulate degradation, rather
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- NHS App to revolutionise digital health and care with major digital updates by 2023
- A new era for UK-Japanese scientific research relations
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
